menu
    • menu

    Company profile for Sarepta Therapeutics

    NEW Drugs in Dev: 21
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our vision is to transform how the world approaches the treatment of serious and life-threatening diseases by unlocking the potential of RNA-based technologies. Recognizing the complexity of this goal, we focus on rare neuromuscular diseases which represent tremendous unmet needs—areas in which new therapies have the potential to make dramatic improvements in the lives of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Sarepta TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    215 First Street Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.sarepta.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/sarepta-therapeutics
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/sarepta

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Duchenne Innovation Thrives For Real Progress
    Duchenne Innovation Thrives For Real Progress

    21 Apr 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/opinion-as-duchenne-innovation-booms-lets-ensure-it-becomes-real-progress

    BIOSPACE
    21 Apr 2026
    Share Share
    Sarepta Overcomes Gene Therapy Setback With Early RNA Therapy
    Sarepta Overcomes Gene Therapy Setback With Early RNA Therapy

    26 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/sarepta-pushes-past-gene-therapy-debacle-as-rna-therapies-show-early-promise

    BIOSPACE
    26 Mar 2026
    Share Share
    Sarepta's Big Bet On Arrowhead's Sirna Assets Yields Early Data
    Sarepta's Big Bet On Arrowhead's Sirna Assets Yields Early Data

    25 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sareptas-big-bet-arrowheads-sirna-assets-yields-early-data

    FIERCE BIOTECH
    25 Mar 2026
    Share Share
    Sarepta To Share siRNA Data In FSHD1, DM1
    Sarepta To Share siRNA Data In FSHD1, DM1

    24 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260324252978/en/Sarepta-to-Share-First-Clinical-Data-from-siRNA-Pipeline-Targeting-FSHD1-and-DM1

    BUSINESSWIRE
    24 Mar 2026
    Share Share
    Sarepta Eyes FDA Nod for Duchenne Exon Skippers Despite Trial
    Sarepta Eyes FDA Nod for Duchenne Exon Skippers Despite Trial

    19 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/sarepta-plans-fda-run-for-duchenne-exon-skippers-despite-confirmatory-trial-failure

    BIOSPACE
    19 Mar 2026
    Share Share
    Sarepta Provides Regulatory Update on Amondys 45 and Vyondys 53
    Sarepta Provides Regulatory Update on Amondys 45 and Vyondys 53

    19 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260319684949/en/Sarepta-Provides-Regulatory-Update-on-AMONDYS-45-and-VYONDYS-53

    BUSSINESSWIRE
    19 Mar 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Sarepta Therapeutics and get a quotation

    Sarepta Therapeutics is a supplier offers 2 products (APIs, Excipients or Intermediates).

    Find SRP-2001 DRUG SUBSTANCE bulk offered by Sarepta Therapeutics

    Find AVI 4126 bulk offered by Sarepta Therapeutics

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search